UBP 1213
Alternative Names: UBP 1213sc; UBP1213Latest Information Update: 28 Jul 2025
At a glance
- Originator Wuhan Huaxin Kangyuan Biopharma
- Developer Shanghai Junshi Biosciences
- Class Monoclonal antibodies
- Mechanism of Action B cell activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Systemic lupus erythematosus
Most Recent Events
- 28 Jul 2025 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus(In volunteers) in China (SC, Injection)
- 27 Jun 2022 Phase-I clinical trials in Systemic lupus erythematosus (In volunteers) in China (SC) (Shanghai Junshi Biosciences) (CTR20220340)
- 30 Aug 2021 The National Medical Products Administration (NMPA) of China approves IND application for UBP 1213sc in Systemic lupus erythematosus